Morgan Conn - Pharvaris Chief Officer

PHVS Stock  USD 22.36  1.81  7.49%   

Insider

Morgan Conn is Chief Officer of Pharvaris BV
Age 55
Address Emmy Noetherweg 2, Leiden, Netherlands, 2333 BK
Phone31 71 203 6410
Webhttps://pharvaris.com

Morgan Conn Latest Insider Activity

Tracking and analyzing the buying and selling activities of Morgan Conn against Pharvaris stock is an integral part of due diligence when investing in Pharvaris. Morgan Conn insider activity provides valuable insight into whether Pharvaris is net buyers or sellers over its current business cycle. Note, Pharvaris insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pharvaris'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Morgan Conn over a month ago
Insider Trading

Pharvaris Management Efficiency

The company has return on total asset (ROA) of (0.2679) % which means that it has lost $0.2679 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4505) %, meaning that it created substantial loss on money invested by shareholders. Pharvaris' management efficiency ratios could be used to measure how well Pharvaris manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.26 in 2024. At this time, Pharvaris' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 885.3 K in 2024, whereas Return On Tangible Assets are likely to drop (0.27) in 2024.
Pharvaris BV currently holds 238.91 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Pharvaris BV has a current ratio of 12.59, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Pharvaris' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

D UmplebyChevron Corp
62
Jo LevyIntel
N/A
Mario GarciaThe Coca Cola
62
Thomas LeonardiThe Travelers Companies
66
William HaitJohnson Johnson
71
Dirk BrinckmanJohnson Johnson
N/A
Claire BramleyHP Inc
43
Saadia MadsbjergThe Coca Cola
43
Nigel HearneChevron Corp
56
Julie JacobsHP Inc
57
Christoph SchellHP Inc
48
Orit KeinanNahonHP Inc
N/A
FCCP MDBright Minds Biosciences
61
Anna NewsomThe Travelers Companies
N/A
Judy GlazerHP Inc
N/A
Greg BaxterHP Inc
N/A
Al WilliamsChevron Corp
N/A
Keyvan EsfarjaniIntel
N/A
Patrick GelsingerIntel
63
Kristen LudgateHP Inc
61
Elizabeth RobinsonThe Travelers Companies
52
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company was incorporated in 2015 and is based in Leiden, the Netherlands. Pharvaris is traded on NASDAQ Exchange in the United States. Pharvaris BV (PHVS) is traded on NASDAQ Exchange in USA. It is located in Emmy Noetherweg 2, Leiden, Netherlands, 2333 BK and employs 83 people. Pharvaris is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Pharvaris BV Leadership Team

Elected by the shareholders, the Pharvaris' board of directors comprises two types of representatives: Pharvaris inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharvaris. The board's role is to monitor Pharvaris' management team and ensure that shareholders' interests are well served. Pharvaris' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharvaris' outside directors are responsible for providing unbiased perspectives on the board's policies.
Peng MD, Chief Officer
Morgan Conn, Chief Officer
Jochen Knolle, Chief COO
CPA MBA, CEO CoFounder
Joan JD, Chief Officer
Stefan Abele, Chief Officer
Wim Souverijns, Chief Officer
Anne Lesage, Chief Officer
David JD, CFO Secretary
RA MSc, Head Officer
Maryann Cimino, Director Relations
Annick Deschoolmeester, Chief Officer

Pharvaris Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharvaris a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Pharvaris Stock Analysis

When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.